Astrazeneca (AZN) Free Cash Flow (2009 - 2026)

Astrazeneca (AZN) has reported Free Cash Flow for 17 consecutive years, with $547.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Free Cash Flow rose 27.51% year-over-year to $547.0 million; the TTM figure through Mar 2026 stood at -$2.7 billion (down 40.79% YoY), while the FY2025 annual figure was $15.9 billion, up 13.76% from the prior year.
• Free Cash Flow came in at $547.0 million for Q1 2026 at Astrazeneca, up from -$4.6 billion in the prior quarter.
• The five-year high for Free Cash Flow was $686.0 million in Q3 2025, with the low at -$4.6 billion in Q4 2025.
• Average Free Cash Flow over 5 years is -$246.0 million, with a median of $382.0 million recorded in 2024.
• The largest YoY upside for Free Cash Flow was 72.51% in 2025 against a maximum downside of 45.99% in 2025.
• Year by year, Free Cash Flow stood at $253.0 million in 2022, then climbed by 6.72% to $270.0 million in 2023, then sank by 1262.96% to -$3.1 billion in 2024, then tumbled by 45.99% to -$4.6 billion in 2025, then surged by 111.93% to $547.0 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered $547.0 million, -$4.6 billion, and $686.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.